Comparison Of Clinical Outcomes Between 3 Types Of Toric Iols – Enhanced Intermediate Function Monofocal, Low-Added Segmental, And Conventional Monofocal Lens

Published 2022 - 40th Congress of the ESCRS

Reference: PP19.13 | Type: ESCRS 2022 - Posters | DOI: 10.82333/6g51-sc40

Authors: Shinichiro Nakano* ¹ , Ruriko Mori ² , Masaharu Iida ² , Tetsuro Oshika ³

¹Ophthalmology,Ryugasaki Saiseikai Hospital,Ryugasaki,Japan, ²Ophthalmology,RYUGASAKI SAISEIKAI HOSPITAL,Ryugasaki,Japan, ³Ophthalmology,University of Tsukuba,Tsukuba,Japan

Purpose

To compare clinical outcomes of the new enhanced intermediate function toric intraocular lens (T-IOL) with low-added segmental and conventional monofocal T-IOLs.

Setting

Ryugasaki Saiseikai hospital, Ibaraki, Japan

Methods

Eyes with corneal astigmatism over 0.75 diopters (D) meeting all inclusion criteria were implanted with a new enhanced intermediate function monofocal T-IOL (Tecnis Eyhance toric, DIW) or low-added segmental T-IOL (Lentis Comfort toric, LS313 MF15T) or conventional monofocal T-IOL (TECNIS Toric II OptiBlue, ZCW). Uncorrected distance (UDVA), intermediate (UIVA) and near (UNVA) visual acuity, T-IOL alignment, and residual astigmatism were examined at 3-month postoperatively.

Results

22 eyes of 21 cases with Eyhance, 39 eyes of 24 cases with Lentis, and15 cases of 14 eyes with OptiBlue T-IOL were enrolled. UDVA, UIVA, and UNVA logMAR of Eyhance were -0.008, 0.12, and 0.49, respectively. UDVA was comparable to Lentis and OptiBlue (P=0.87, 0.53 respectively). UIVA was comparable to Lentis (P=0.54) and tended to be better than OptiBlue although statistically not significant (P=0.075). UNVA was lower than Lentis (P=0.04) and equivalent to OptiBlue (P=0.07). T-IOL misalignment was 1.73 degrees, which tended to be better than Lentis (P=0.058) and equivalent to OptiBlue (P=0.48). Residual astigmatism was 0.14 D, comparable to Lentis and OptiBlue (P=0.90,0.98).

Conclusions

Eyhance toric T-IOL (DIW) provided intermediate vision comparable to Lentis T-IOL, and rotational stability comparable to OptiBlue T-IOL, and astigmatic correction equivalent to both Lentis and OptiBlue T-IOLs.